BIO-key International (NASDAQ:BKYI) Announces Quarterly Earnings Results

BIO-key International (NASDAQ:BKYI) released its quarterly earnings data on Friday. The technology company reported ($4.01) EPS for the quarter, missing the consensus estimate of ($0.35) by ($3.66), Zacks reports. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $2.40 million. BIO-key International had a negative return on equity of 67.31% and a negative net margin of 50.01%.

Here are the key takeaways from BIO-key International’s conference call:

• Software growth lifted margins: Q3 license-fee revenue rose 39% year over year and reached 86% of total revenue, helping gross margin improve to 90% from 77% and reducing the operating loss 8%. Total revenue nevertheless fell 4%, largely because hardware sales declined.
• International regulated-sector wins expanded the pipeline: BIO-key highlighted new government and financial-services customers, including the Central Bank of Jordan, and said it has added eight Middle East customers in roughly seven months. Management described larger opportunities ahead, but timing and collections remain dependent on customer and partner deployments.
• New U.S. opportunities and product initiatives: A casino resort signed a prepaid, three-year PortalGuard agreement, and BIO-key said its FIDO-certified Passkey:YOU product is nearing launch, with agentic-AI authentication as a potential use case. Management sees partner-led sales and additional verticals as growth opportunities, though adoption is not yet established.
• Balance sheet strengthened: The company retired its remaining note debt, ended the quarter with $2.2 million in cash and $3.1 million of working capital, and said it does not currently expect to need additional capital. Management is targeting profitability as it approaches Q1 2027.
• Reported loss per share was sharply affected by a financing-related accounting item: A non-cash $4.5 million deemed dividend tied to an August warrant inducement brought Q3 net loss available to common stockholders to $5.9 million, or $4 per share, despite improvement in the operating loss. Hardware revenue also fell to $12,000 from $364,000 a year earlier, with a large customer order delayed into smaller shipments.

BIO-key International Stock Down 17.8%

BKYI stock traded down $0.46 during trading on Friday, hitting $2.12. 216,234 shares of the company’s stock traded hands, compared to its average volume of 4,350,114. The firm has a market capitalization of $4.31 million, a P/E ratio of -0.52 and a beta of 0.52. The business has a fifty day simple moving average of $2.46 and a two-hundred day simple moving average of $4.40. BIO-key International has a 1 year low of $1.55 and a 1 year high of $10.70.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of BIO-key International in a report on Thursday, October 15th. Wall Street Zen lowered BIO-key International from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Zacks Research upgraded BIO-key International to a “hold” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce”.

BIO-key International Company Profile

BIO-key International, Inc. (NASDAQ: BKYI) develops biometric authentication and identity and access management solutions. The company helps organizations secure access to applications, networks, devices and data through fingerprint recognition and other authentication methods designed to reduce reliance on passwords. Its product portfolio includes PortalGuard, an identity and access management platform that supports single sign-on, multifactor authentication, self-service password management and access control.